Russell Investments Group Ltd. Purchases 64,236 Shares of Cencora, Inc. $COR

Russell Investments Group Ltd. grew its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 34.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 253,078 shares of the company's stock after purchasing an additional 64,236 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.13% of Cencora worth $76,079,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Deutsche Bank AG purchased a new position in Cencora during the second quarter worth approximately $286,673,000. SEB Asset Management AB purchased a new stake in Cencora in the 1st quarter valued at $134,139,000. Wedge Capital Management L L P NC grew its holdings in Cencora by 31.0% in the 2nd quarter. Wedge Capital Management L L P NC now owns 105,614 shares of the company's stock valued at $29,887,000 after buying an additional 24,968 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Cencora in the 2nd quarter worth $841,000. Finally, Peachtree Investment Partners LLC acquired a new stake in shares of Cencora in the 2nd quarter worth $2,204,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the business's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the sale, the executive vice president directly owned 19,455 shares of the company's stock, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.38% of the stock is currently owned by corporate insiders.

Cencora Trading Up 2.8%

Shares of Cencora stock traded up $9.74 during trading hours on Friday, hitting $359.12. The company's stock had a trading volume of 1,393,211 shares, compared to its average volume of 1,421,795. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The firm has a fifty day moving average of $327.12 and a 200-day moving average of $317.20. The stock has a market cap of $68.53 billion, a price-to-earnings ratio of 20.04, a P/E/G ratio of 1.81 and a beta of 0.58. The company has a debt-to-equity ratio of 3.01, a quick ratio of 0.59 and a current ratio of 0.94.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, topping analysts' consensus estimates of $4.58 by $0.08. The business had revenue of $88.35 billion during the quarter, compared to analysts' expectations of $87.95 billion. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The company's revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.84 EPS. Research analysts forecast that Cencora, Inc. will post 19.58 EPS for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be given a dividend of $0.66 per share. This is a boost from Cencora's previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, November 13th. Cencora's dividend payout ratio (DPR) is 13.39%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on COR. Argus boosted their price target on shares of Cencora from $340.00 to $380.00 and gave the company a "buy" rating in a research report on Tuesday, October 20th. Citigroup restated a "buy" rating on shares of Cencora in a research report on Thursday, August 6th. Weiss Ratings raised shares of Cencora from a "buy (b-)" rating to a "buy (b)" rating in a research note on Tuesday, October 6th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $390.00 to $413.00 and gave the company an "overweight" rating in a report on Tuesday, November 10th. Finally, UBS Group decreased their target price on shares of Cencora from $430.00 to $400.00 and set a "buy" rating on the stock in a report on Friday, October 16th. Twelve research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $368.14.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.